Delcath Systems Inc (DCTH) Stock Price, Quote & News

Company Profile

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal...

Industry: Medical Devices

Sector: Healthcare

Phone: 212-489-2100

Fax: 212-489-2102

Website: www.delcath.com

Address:

566 Queensbury Avenue, New York, United States

RemitTekram Jul. 16 at 12:14 PM

$DCTH Maaaybe....🤞

0 · Reply

alexpitti Jul. 16 at 5:52 AM

$DCTH im bullish on mum and icc

0 · Reply

TradeMadeNow Jul. 15 at 11:33 PM

$DCTH it looks to me like it's about ready to channel up again.

1 · Reply

Andyc545 Jul. 15 at 10:45 PM

$DCTH Ugh I was really into this one but this chart is absolute garbage..

1 · Reply

mar99 Jul. 15 at 8:38 PM

$DCTH So Dcth now down about 40% from high reached less than 2 months ago as the market hits new high after new high.

1 · Reply

alexpitti Jul. 15 at 8:33 PM

Our stock $DCTH bore the brunt of this 1% day

0 · Reply

HypnoTrader Jul. 15 at 7:56 PM

$DCTH more relevant question would be how many are living with liver metastasis at the same time. That is the patient population.

2 · Reply

Real_Phil Jul. 15 at 7:52 PM

$DCTH Is Grok wrong? https://grok.com/share/c2hhcmQtMw%3D%3D_63fca813-a331-464c-9e1b-1e308e259b69 My guess is it might be close as of right now, but it the patient population will increase with good CHOPIN results.

0 · Reply

Dryrr Jul. 15 at 7:49 PM

$DCTH todays price action has been quite similar to IWM (russell 2000) tho..

0 · Reply

Ryan40T2Z Jul. 15 at 7:48 PM

$DCTH @TradingSecretsYT what you thinking? Buy at $11 or under $10?

0 · Reply

Delcath Systems: Growing Fast, But Business Model Is Fragile

May 22, 2025, 7:00 AM EDT - 7 weeks ago

Delcath Systems Issues Full Year 2025 Guidance

May 18, 2025, 8:25 AM EDT - 2 months ago

Delcath Systems: Q1 Earnings Show A Growth Spurt And Switch To Execution

May 15, 2025, 4:30 PM EDT - 2 months ago

Delcath Systems to Participate at the Craig-Hallum 22nd Annual Investor Conference

May 9, 2025, 5:30 PM EDT - 2 months ago

Delcath Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 8, 2025, 10:55 AM EDT - 2 months ago

Delcath Systems, Inc. (DCTH) Q1 2025 Earnings Call Transcript

May 8, 2025, 7:30 AM EDT - 2 months ago

Delcath Systems Reports First Quarter 2025 Results and Business Highlights

Apr 28, 2025, 8:30 AM EDT - 2 months ago

Delcath Systems Announces FDA Clearance of IND Application for Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Breast Cancer

Apr 24, 2025, 4:01 PM EDT - 2 months ago

Delcath Systems to Host First Quarter 2025 Earnings Call

Apr 9, 2025, 5:00 PM EDT - 3 months ago

Delcath Systems Announces Publication of Comparative Analysis from Randomized Portion of FOCUS Study in Metastatic Uveal Melanoma

Apr 2, 2025, 11:49 AM EDT - 3 months ago

Hospitals Experience FOMO In Adopting Delcath's PHP Treatment

Mar 24, 2025, 4:01 PM EDT - 4 months ago

Delcath Systems to Participate at the Canaccord Genuity Horizons in Oncology Virtual Conference

Mar 14, 2025, 4:01 PM EDT - 4 months ago

Delcath Systems, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Mar 6, 2025, 2:17 PM EST - 4 months ago

Delcath Systems, Inc. (DCTH) Q4 2024 Earnings Call Transcript

Mar 6, 2025, 8:00 AM EST - 4 months ago

Delcath Systems Reports Fourth Quarter and Full Year 2024 Results

Feb 20, 2025, 8:30 AM EST - 5 months ago

Delcath Systems to Host Fourth Quarter and Full Year 2024 Earnings Call

Feb 14, 2025, 8:30 AM EST - 5 months ago

Delcath Systems Announces Update to National Comprehensive Cancer Network Clinical Practice Guidelines for the Treatment of Metastatic Uveal Melanoma

Jan 30, 2025, 7:06 PM EST - 5 months ago

Biotech walks a 'tightrope' amid unclear funding, regulations

ELVN IBB

Jan 28, 2025, 4:01 PM EST - 6 months ago

Delcath Systems to Participate at the BTIG Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Jan 13, 2025, 8:00 AM EST - 6 months ago

Delcath Systems Announces Preliminary Fourth Quarter and Full Year 2024 Financial Results

Jan 3, 2025, 4:01 PM EST - 6 months ago

Delcath Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Dec 30, 2024, 8:00 AM EST - 7 months ago

Delcath Systems Announces Additional $16.3 Million in Funding From Series E and E1 Warrant Exercises

Dec 2, 2024, 8:30 AM EST - 8 months ago

Delcath Systems Announces FDA Clearance of IND Application for Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Colorectal Cancer

Nov 20, 2024, 7:50 AM EST - 8 months ago

Delcath Begins Platform Expansion With Two Phase 2 Trials

Nov 18, 2024, 7:09 AM EST - 8 months ago

Delcath Systems: Q3 Earnings Reveal HEPZATO KIT And CHEMOSAT Growth

Nov 8, 2024, 12:30 PM EST - 8 months ago

Delcath Systems Inc (DCTH) Q3 2024 Earnings Call Transcript

Nov 8, 2024, 8:00 AM EST - 8 months ago

Delcath Systems Reports Third Quarter 2024 Results and Business Highlights

Nov 1, 2024, 4:01 PM EDT - 9 months ago

Delcath Systems to Participate in Upcoming Investor Conferences

Oct 25, 2024, 8:30 AM EDT - 9 months ago

Delcath Systems to Host Third Quarter 2024 Earnings Call

Oct 17, 2024, 8:30 AM EDT - 9 months ago

Delcath Systems Announces Preliminary Third Quarter 2024 Revenue Results

Sep 16, 2024, 8:30 AM EDT - 10 months ago

Delcath Systems Announces New Data Presented at ESMO 2024 Demonstrating Efficacy of HEPZATO KIT™ in Metastatic Uveal Melanoma Subgroups

Aug 28, 2024, 4:01 PM EDT - 11 months ago

Delcath Systems, Inc. Announces Positive Results from Independent Study on Liver-Directed Therapy for Uveal Melanoma Patients

Aug 28, 2024, 4:01 PM EDT - 11 months ago

Delcath Systems to Participate at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 27, 2024, 8:30 AM EDT - 11 months ago

Delcath Systems, Inc. Announces Positive Outcomes from Independent Study on Hepatic Perfusion for Uveal Melanoma Patients

Aug 26, 2024, 4:01 PM EDT - 11 months ago

Delcath Systems, Inc. Announces Promising Results from Independent Study on Repeated Hepatic Chemosaturation for Liver Tumors

Aug 23, 2024, 3:30 PM EDT - 11 months ago

Undercovered Dozen: Delcath Systems, Bavarian Nordic, Tempus AI, Journey Energy +

TEM

Aug 20, 2024, 8:30 AM EDT - 11 months ago

Delcath Systems Announces Poster Presentation at the 2024 ESMO Congress

Aug 18, 2024, 10:03 PM EDT - 11 months ago

Delcath Is On Schedule For A Monster 2025: A Platform Valuation Awaits

Aug 6, 2024, 1:54 AM EDT - 1 year ago

Delcath Systems Inc (DCTH) Q2 2024 Earnings Call Transcript

Aug 5, 2024, 4:01 PM EDT - 1 year ago

Delcath Systems Reports Second Quarter 2024 Results and Business Highlights

Aug 5, 2024, 8:30 AM EDT - 1 year ago

Delcath Systems Announces CMS Approval for NTAP for HEPZATO KIT™

Jul 22, 2024, 4:01 PM EDT - 1 year ago

Delcath Systems to Host Second Quarter 2024 Earnings Call

May 28, 2024, 9:30 AM EDT - 1 year ago

Delcath Systems Announces Appointment of Bridget Martell, MA, MD to Delcath's Board of Directors

May 14, 2024, 2:16 PM EDT - 1 year ago

Delcath Systems Inc (DCTH) Q1 2024 Earnings Call Transcript

May 14, 2024, 7:30 AM EDT - 1 year ago

Delcath Systems Reports First Quarter 2024 Results and Business Highlights

May 7, 2024, 8:30 AM EDT - 1 year ago

Delcath Systems to Host First Quarter 2024 Earnings Call

May 6, 2024, 9:00 AM EDT - 1 year ago

Publication of Results from Pivotal FOCUS Study in Metastatic Uveal Melanoma Patients treated with HEPZATO KIT

May 3, 2024, 5:15 PM EDT - 1 year ago

Delcath Systems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 26, 2024, 12:49 PM EDT - 1 year ago

Delcath Systems Inc (DCTH) Q4 2023 Earnings Call Transcript

Mar 26, 2024, 7:30 AM EDT - 1 year ago

Delcath Systems Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update

RemitTekram Jul. 16 at 12:14 PM

$DCTH Maaaybe....🤞

0 · Reply

alexpitti Jul. 16 at 5:52 AM

$DCTH im bullish on mum and icc

0 · Reply

TradeMadeNow Jul. 15 at 11:33 PM

$DCTH it looks to me like it's about ready to channel up again.

1 · Reply

Andyc545 Jul. 15 at 10:45 PM

$DCTH Ugh I was really into this one but this chart is absolute garbage..

1 · Reply

mar99 Jul. 15 at 8:38 PM

$DCTH So Dcth now down about 40% from high reached less than 2 months ago as the market hits new high after new high.

1 · Reply

alexpitti Jul. 15 at 8:33 PM

Our stock $DCTH bore the brunt of this 1% day

0 · Reply

HypnoTrader Jul. 15 at 7:56 PM

$DCTH more relevant question would be how many are living with liver metastasis at the same time. That is the patient population.

2 · Reply

Real_Phil Jul. 15 at 7:52 PM

0 · Reply

Dryrr Jul. 15 at 7:49 PM

$DCTH todays price action has been quite similar to IWM (russell 2000) tho..

0 · Reply

Ryan40T2Z Jul. 15 at 7:48 PM

$DCTH @TradingSecretsYT what you thinking? Buy at $11 or under $10?

0 · Reply

mar99 Jul. 15 at 7:32 PM

$DCTH Seems like management should address the ongoing massacre in the stock and whatever rumors are out there causing this. Otherwise another 3-4 weeks until they report earnings and this destructive action might continue until then.

0 · Reply

HypnoTrader Jul. 15 at 7:14 PM

$DCTH a. Are you sure there aren't any shenanigans with CMS? A lot of stocks are suffering. b. Seems to be a general bear market with device makers and other medical stocks due to Medicare cuts. c. Long term competitive threats are real.

1 · Reply

alexpitti Jul. 15 at 7:13 PM

True carnage today in $DCTH $RARE $CLPT $RCEL

0 · Reply

Standard_Invest Jul. 15 at 7:11 PM

$DCTH Guess short volume 3x end of june.

1 · Reply

Dryrr Jul. 15 at 7:08 PM

$DCTH i dont get the price action

1 · Reply

Standard_Invest Jul. 15 at 7:07 PM

$DCTH phu Dunno should hold until 4th august

0 · Reply

mar99 Jul. 15 at 6:59 PM

$DCTH This is crazy. The relentless selling just doesn’t end.

0 · Reply

Ryan40T2Z Jul. 15 at 6:20 PM

$DCTH been watching for a while… feels like bottom

0 · Reply

Zzzquil Jul. 15 at 5:01 PM

$DCTH this outfit is making money, shouldn’t it be holding up better than the clinical bios which need cash

0 · Reply

titan888 Jul. 15 at 3:03 PM

$DCTH a good time to buy

0 · Reply

precise Jul. 15 at 2:32 PM

$DCTH Someones VWAP dumping. Why do they want out so bad? Gonna build position before earnings

2 · Reply

HypnoTrader Jul. 14 at 10:09 PM

$DCTH looks like maximum CMS for hepzato did not change between 2024 and 2025? $787K?

0 · Reply

Market Cap	413.39M
Revenue (ttm)	37.21M
Net Income (ttm)	-26.39M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	34.36
Profit Margin	-70.92%
Debt to Equity Ratio	0.00

Volume	774,300
Avg Vol	709,174
Day's Range	N/A - N/A
Shares Out	34.83M
Stochastic %K	3%
Beta	0.87
Analysts	Strong Sell
Price Target	$24.40